Healio Minute – Détails, épisodes et analyse

In this edition, blue-collar workers more likely to miss work or quit due to psoriatic arthritis, infliximab biosimilar increase after release of a third option and more.

Read the full coverage here:

Blue-collar workers more likely to miss work, quit due to psoriatic arthritis

Infliximab biosimilar uptake rapidly increased only after release of a third option

National Psoriasis Foundation to honor leaders at 2025 Commit to Cure Gala

Safety checklist compiles clinically important DMARD warnings in one place

Guselkumab demonstrates long-term efficacy, safety in psoriasis

References:

Colla N, et al. Clin Rheumatol. 2024;doi:10.1007/s10067-024-07077-1.

Gargiulo L, et al. J Drugs Dermatol. 2024;doi:10.36849/JDD.7486R1.

Press Release

Roberts ET, et al. Arthritis Rheumatol. 2024;doi:10.1002/art.42963.

Skaarup L, et al. Drug Saf. 2024;doi:10.1007/s40264-024-01461-1.

In this edition, FDA approves first subcutaneous anti-PD-L1 cancer immunotherapy, ivonescimab ‘may be a new standard’ and more.

Read the full coverage here:

FDA approves first subcutaneous anti-PD-L1 cancer immunotherapy

Ivonescimab extends PFS vs. pembrolizumab in advanced NSCLC, may be ‘a new standard’

Perioperative nivolumab improves outcomes in resectable NSCLC

Despite progress, barriers to lung cancer biomarker testing persist

Atezolizumab regimen ‘merits further study’ for unresectable NSCLC

References:

Forde PM, et al. Abstract 3589. Presented at: IASLC World Conference on Lung Cancer; Sept. 7-10, 2024; San Diego.

Press Release

Ross HJ, et al. JAMA Oncol. 2024;doi:10.1001/jamaoncol.2024.1897.

Smeltzer M, et al. Abstract 3000. Presented at: IASLC World Conference on Lung Cancer; Sept. 7-10, 2024; San Diego.

Zhou C, et al. Abstract 2700. Presented at: IASLC World Conference on Lung Cancer; Sept. 7-10, 2024; San Diego.

In this edition, screening program identifies airways disease in previously undiagnosed COPD, positive results show benefits of subcutaneous bispecifics and more.

Read the full coverage here:

Lung cancer screening program identifies airways disease in previously undiagnosed COPD

Positive results in lung cancer show benefits of subcutaneous bispecifics

Adagrasib delays progression of pretreated KRAS-mutant lung cancer

Durvalumab extends survival in limited-stage small-cell lung cancer

Osimertinib delays progression ‘way more’ than hoped in EGFR-mutant lung cancer

References:

Bernstein E, et al. JCO Precis Oncol. 2024;doi:10.1200/po.23.00447.

Leighl NB, et al. Abstract LBA8505. Presented at: ASCO Annual Meeting; May 30–June 3, 2024; Chicago.

Ramalingam SS, et al. Abstract LBA4. Presented at: ASCO Annual Meeting; May 31-June 4, 2024: Chicago.

Seigo MA, et al. Pulmonary comorbidities, respiratory symptoms, and spirometry in a real-world, urban lung cancer screening program. Presented at: American Thoracic Society International Conference; May 17-22, 2024; San Diego.

Spigel DR, et al. Abstract LBA3. Presented at: ASCO Annual Meeting; May 31-June 4, 2024: Chicago.

In this edition, Incidental respiratory findings on low-dose CT lung cancer screening common; lack of guideline-concordant treatment for early-stage non-small cell lung cancer common; women at greater risk for more severe adverse events from cancer treatments, and more.

Read the full coverage here:

Incidental respiratory findings on low-dose CT lung cancer screening common

Lack of guideline-concordant treatment for early-stage non-small cell lung cancer common

Women at greater risk for more severe adverse events from cancer treatments

Visual, quantitative CT emphysema assessments linked to higher odds of lung cancer

Acetaminophen may reduce immunotherapy efficacy in patients with cancer

References:

Bessede A, et al. Abstract LBA12000. Presented at: ASCO Annual Meeting; June 3-7, 2022; Chicago.

Kehl KL, et al. JAMA Oncol. 2022;doi: 10.1001/jamaoncol.2022.0039.

Pinsky PF, et al. Chest. 2022;doi:10.1016/j.chest.2021.11.015.

Unger JM, et al. J Clin Oncol. 2022;doi:10.1200/JCO.21.02377.

Yang X, et al. Radiol. 2022;doi:10.1148/212904.

In this week’s edition, women are less likely than men to return to work after large vessel occlusion stroke; cognitive impairment, headaches and CVD are more common in former college football players; veterans, providers support the addition of integrative medicine for chronic headaches; and more.

Read the full coverage here:

Women less likely than men to return to work after large vessel occlusion stroke

Cognitive impairment, headaches, CVD more common in former college football players

Veterans, providers support addition of integrative medicine for chronic headaches

New blood biomarker may lead to early diagnosis of frontotemporal dementia

Phase 2 trial shows promising results for oral Parkinson’s treatment

References:

Hahn M, et al. Stroke. 2022;doi:10.1161/STROKEAHA.121.037386.

Phelps A, et al. JAMA Netw Open. 2022;doi:10.1001/jamanetworkopen.2022.8775.

Press Release

Press Release

Press Release

In this edition, late-stage colorectal, breast cancer diagnoses increase after start of COVID-19 pandemic; chemicals found in hair products increase viability of breast cancer cells in Black women; continued CDK 4/6 inhibition after breast cancer progression may benefit some patients; and more.

Read the full coverage here:

Late-stage colorectal, breast cancer diagnoses increase after start of COVID-19 pandemic

Chemicals found in hair products increase viability of breast cancer cells in Black women

Continued CDK 4/6 inhibition after breast cancer progression may benefit some patients

Some older women with luminal A breast cancer can safely forgo radiotherapy, study shows

Sacituzumab govitecan significantly extends PFS in advanced breast cancer subset

References:

Zhou JZ, et al. JAMA Netw Open. 2022;doi:10.1001/jamanetworkopen.2021.48581.

Trevino L, et al. RF22 | PMON05. Presented at: ENDO Annual Meeting; June 11-14, 2022; Atlanta (hybrid meeting).

Kalinsky K, et al. Abstract LBA1004. Presented at: ASCO Annual Meeting; June 3-7, 2022; Chicago.

Source: Whelan TJ, et al. Abstract LBA501. Presented at: ASCO Annual Meeting; June 3-7, 2022; Chicago.

Rugo HS, et al. Abstract LBA1001. Presented at: ASCO Annual Meeting; June 3-7, 2022; Chicago.

In this week’s edition, CAR-T ‘robustly effective’ in younger patients with deadly form of brain cancer; SARS-CoV-2 linked to range of neurological diseases; Increased mortality risk for men with type 1 diabetes, regardless of cognitive ability; and more.

Read the full coverage here:

Steerable microcatheter nets FDA 510(k) clearance for neurologic, peripheral, coronary use

CAR-T ‘robustly effective’ in younger patients with deadly form of brain cancer

SARS-CoV-2 linked to range of neurological diseases

Risk for major adverse CV events elevated with type 2 diabetes, cognitive impairment

Increased mortality risk for men with type 1 diabetes, regardless of cognitive ability

References:

Press Release

Majzner RG, et al. Abstract CT001. Presented at: American Association for Cancer Research Annual Meeting; April 8-13, 2022; New Orleans.

Klein RS, et al. Neurobiology of COVID-19. Presented at: American Academy of Neurology annual meeting; April 2-7, 2022; Seattle.

Cukierman-Yaffe T, et al. J Clin Endocrinol Metab. 2022;doi:10.1210/clinem/dgac200

Dybjer E, et al. Diabet Med. 2022;doi:10.1111/dme.14806.

In this edition, AYA cancer survivors are at higher risk for death due to second primary cancers; a radiation technique reduces symptomatic esophagitis in patients with advanced lung cancer; a phase 3 trial of tiragolumab plus atezolizumab misses its co-primary endpoint; and more.

Read the full coverage here:

AYA cancer survivors at higher risk for death due to second primary cancers

Radiation technique reduces symptomatic esophagitis in patients with advanced lung cancer

Phase 3 trial of combination for advanced lung cancer misses co-primary endpoint

As proton beam therapy use for cancer increased, ‘so did the racial disparity in receipt’

Entrectinib induces durable, intracranial responses in NTRK fusion-positive solid tumors

References:

Sung H, et al. J Natl Cancer Inst. 2022;doi:10,1093/jnci/djac091.

Louie AV, et al. JAMA Oncol. 2022:doi:10.1001/jamaoncol.2021.7664.

Press Release

Nogueira LM, et al. JAMA Netw Open. 2022;doi:10.1001/jamanetworkopen.2022.8970.

Demetri GD, et al. Clin Cancer Res. 2022;doi:10.1158/1078-0432.CCR-21-3597.

In this week’s edition, anxiety, depression worse among older men with vision impairment; emerging therapeutics may improve outcomes in pediatric patients with rare disorders; glioblastoma presents roadblock to successful immunotherapy; and more.

Read the full coverage here:

MRI findings key pathology markers of 4R-tauopathies

Emerging therapeutics may improve outcomes in pediatric patients with rare disorders

Together Senior Health launches platform to reduce memory loss in AD, dementia

Anxiety, depression worse among older men with vision impairment

Glioblastoma presents roadblock to successful immunotherapy

References:

Carlos AF, et al. Tau histopathological lesion type correlates of structural magnetic resonance imaging and diffusion tensor imaging biomarkers in 4-repeat tauopathies. Presented at: American Academy of Neurology annual meeting; April 2-7, 2022; Seattle.

Emrick L, et al. Emerging therapeutics for rare pediatric genetic disorders. Presented at: American Academy of Neurology annual meeting; April 2-7, 2022; Seattle.

Press Release

Gascoyne B, et al. Int Health. 2022;doi:10.1093/inthealth/ihab070

Kumthekar P. AAN year in review: neuro oncology. Presented at: American Academy of Neurology annual meeting; April 2-7, 2022; Seattle.

Read the full coverage here:

In this edition, diet, genetics and family history play role in AMD progression; omega-3 fatty acids may improve vision in dry AMD; long-term dopamine treatment may delay onset of diabetic retinopathy; and more.

Diet, genetics and family history play role in AMD progression

Omega-3 fatty acids may improve vision in dry AMD

Long-term dopamine treatment may delay onset of diabetic retinopathy

Anti-VEGF injections decrease aqueous VEGF levels in diabetic retinopathy

Novel ERG method aids in monitoring patients with posterior uveitis

References:

Williams BK. What to do for your patient with early dry AMD. Presented at: American Society of Cataract and Refractive Surgery meeting; April 22-26, 2022; Washington.

Prokopiou E, et al. A prospective, randomised, multicenter, double-blind, placebo-controlled study assessing the potential effects of omega-3 fatty acids supplementation on dry age-related macular degeneration and Stargardt disease. Presented at: Association for Research in Vision and Ophthalmology meeting; May 1-4, 2022; Denver.

Allen RS, et al. Dopamine treatment delays diabetic retinopathy onset in a retrospective study. Presented at: Association for Research in Vision and Ophthalmology meeting; May 1-4, 2022; Denver.

Mynampati BK, et al. Aqueous levels of VEGF decrease after serial intravitreal injections of anti-VEGF agents in patients with diabetic retinopathy. Presented at: Association for Research in Vision and Ophthalmology meeting; May 1-4, 2022; Denver.

Than NTT, et al. Flicker ERG findings in posterior uveitis. Presented at: Association for Research in Vision and Ophthalmology meeting; May 1-4, 2022; Denver.